PanGenomic Health Expands Investor Relations Agreement with Fairfax Partners

Vancouver, British Columbia, Canada, October 7, 2025 – TheNewswire – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that it has expanded its engagement with Fairfax Partners Inc. (“Fairfax”) of Vancouver, BC for the provision of investor relations, communications infrastructure and marketing services. The original services agreement with Fairfax was announced by the Company on June 20, 2025.

The amended services agreement with Fairfax will remain in effect for a period of twelve (12) months commencing on October 6, 2025. In accordance with the terms and conditions of the services agreement and as consideration for the services provided by Fairfax, the Company has agreed to pay a monthly cash fee of $7,500, plus applicable taxes. In addition, the Company has agreed to allocate up to $400,000, at the Company’s discretion, over a 12-month period to be spent by Fairfax in coordination with the Company towards digital marketing and media activities to support brand visibility, stakeholder engagement, and commercial growth.  All digital marketing and media activities will be pre-approved by the Company.

Fairfax Partners Inc. is an unrelated third party service provider.  Fairfax Partners Inc., including its owners and directors, does not hold, directly or indirectly, any ownership or interest in the securities of the Company.

Fairfax has an address at 1221 Bidwell St., Vancouver, BC, V6G 0B1, Canada, and can be reached by telephone at +1 604-305-5369 or by email at [email protected].

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Registered as a British Columbia benefit company, PanGenomic Health’s mission is to promote alternative health solutions tailored to the health profile of each individual. To learn more about PanGenomic Health’s products and services: www.pangenomic.com or email: [email protected].

For more information, please contact:

This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health’s disclosure documents which can be found under PanGenomic Health’s profile on www.sedarplus.ca.  These risk factors include the possibility of delays in PanGenomic Health’s development efforts, PanGenomic Health not having sufficient financial resources to complete its development efforts in a timely manner and other risks, including those that may be outside of the control of PanGenomic Health.  Except as required under applicable securities legislation, PanGenomic Health undertakes no obligation to publicly update or revise forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

Copyright (c) 2025 TheNewswire – All rights reserved.